Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06784557 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Ezetimibe on Gut Microbiota

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 20, 2025 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Yonsei University
239 trials monitored
See 2 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Ezetimibe exerts its primary effects by inhibiting intestinal cholesterol absorption through the NPC1L1 protein. Beyond this, its impact on gut microbiota remains an area of interest. Gut microbiota has been implicated in cholesterol metabolism and CVD pathogenesis through metabolic and non-metabolic pathways. Modulating gut microbiota has been explored as a potential strategy to prevent CVDs. Despite its intestinal mechanism, the influence of ezetimibe on gut microbiota composition has not been thoroughly investigated. Future studies are needed to elucidate its potential interactions with gut microbial communities and their implications for cholesterol metabolism and cardiovascular health.
Trial Details
NCT Number NCT06784557
Lead Sponsor Yonsei University
Conditions
(from sponsor)		 Atherosclerotic Cardiovascular Disease With Dyslipidemia
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov